Diaprost AB
Share:
Subscribe:

Johan Drott CEO Diaprost AB

Mon, Feb 22, 2021 08:00 CET

Medium resolution

Original resolution

Subscribe

Related Releases

Diaprost Licenses its novel Theranostic Antibody, hu5A10, to Radiopharm Theranostics for Development in the Treatment and Diagnosis of Prostate Cancer. Tue, Sep 28, 2021 09:00 CET

Diaprost AB Acquires Rights to use of PSA Antibodies from Leading New York Cancer Center Tue, Aug 25, 2020 08:00 CET

Diaprost announces Exercise of Option under the terms of its Research and Option Agreement with a leading Pharmaceutical company Tue, Jan 21, 2020 10:50 CET